Индивидуализована или модификована хемотерапија (прилагођавање или одлагање дозе)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Извор‎: Leuk Res 2011;35(8):991-7.

Индекс‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (отвара нови прозор)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (отвара нови прозор)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Извор‎: Br J Haematol 2014;165(4):497-503.

Индекс‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (отвара нови прозор)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (отвара нови прозор)

Dainer PM, Knupp CL, Sartiano GP.

Извор‎: Am J Hematol 1992;40(2):156-7.

Индекс‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (отвара нови прозор)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (отвара нови прозор)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Извор‎: Lancet Oncol 2013;14(6):525-33.

Индекс‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (отвара нови прозор)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (отвара нови прозор)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Извор‎: N Engl J Med 2020;383(7):617-29.

Индекс‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (отвара нови прозор)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (отвара нови прозор)

El Chaer F, Ballen KK

Извор‎: Br J Haematol 2020;190(5):696-707.

Индекс‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (отвара нови прозор)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (отвара нови прозор)

Emadi A, Bade NA, Stevenson B, Singh Z.

Извор‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Индекс‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (отвара нови прозор)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (отвара нови прозор)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Извор‎: J Clin Oncol 2009;27(28):4733-40.

Индекс‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (отвара нови прозор)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (отвара нови прозор)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Извор‎: Int J Hematol 1997;65(4):415-6.

Индекс‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (отвара нови прозор)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (отвара нови прозор)

Garelius H, Grund S, Stockelberg D.

Извор‎: Clin Case Rep 2015;3(5):287-90.

Индекс‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (отвара нови прозор)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (отвара нови прозор)

Juliusson G.

Извор‎: Am J Hematol 1996;53(1):49.

Индекс‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (отвара нови прозор)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (отвара нови прозор)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Извор‎: Eur J Haematol 2004;72(4):264-7.

Индекс‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (отвара нови прозор)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (отвара нови прозор)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Извор‎: Am J Hematol 1996;51(3):251-2.

Индекс‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (отвара нови прозор)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (отвара нови прозор)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Извор‎: Hematol Oncol 2014;32(1):40-6.

Индекс‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (отвара нови прозор)

Cytarabine dose for acute myeloid leukemia. (отвара нови прозор)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Извор‎: N Engl J Med 2011;364(11):1027-36.

Индекс‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (отвара нови прозор)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (отвара нови прозор)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Извор‎: Bone Marrow Transplant 2003;32(4):433-6.

Индекс‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (отвара нови прозор)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (отвара нови прозор)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Извор‎: N Engl J Med. 2022;386(16):1519-31.

Индекс‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (отвара нови прозор)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (отвара нови прозор)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Извор‎: Gynecol Oncol 2012;124(2):221-4.

Индекс‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (отвара нови прозор)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (отвара нови прозор)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Извор‎: Leuk Res Rep. 2022 25;18:100355.

Индекс‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (отвара нови прозор)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (отвара нови прозор)

Norfolk DR, Wade P, Carter R.

Извор‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (отвара нови прозор)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (отвара нови прозор)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Извор‎: Leuk Lymphoma. 2019;60(9):2324-7.

Индекс‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (отвара нови прозор)

Hematopoietic growth factors: personalization of risks and benefits. (отвара нови прозор)

Puhalla S, Bhattacharya S, Davidson NE.

Извор‎: Mol Oncol 2012;6(2):237-41.

Индекс‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (отвара нови прозор)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (отвара нови прозор)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Извор‎: Leuk Lymphoma 2021;62(6):1497-501.

Индекс‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (отвара нови прозор)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (отвара нови прозор)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Извор‎: Blood 2020;135(7):463-71.

Индекс‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (отвара нови прозор)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (отвара нови прозор)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Извор‎: Bone Marrow Transplant 2005;36(8):715-20.

Индекс‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (отвара нови прозор)

A Mexican way to cope with stem cell grafting. (отвара нови прозор)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Извор‎: Hematology 2012;17 Suppl 1:S195-7.

Индекс‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (отвара нови прозор)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (отвара нови прозор)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Извор‎: Blood 2009;113(9):1875-91.

Индекс‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (отвара нови прозор)

SCT in Jehovah's Witnesses: the bloodless transplant. (отвара нови прозор)

Sloan JM, Ballen K.

Извор‎: Bone Marrow Transplant 2008;41(10):837-44.

Индекс‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (отвара нови прозор)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (отвара нови прозор)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Извор‎: Cancer 2006;107(8):1839-43.

Индекс‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (отвара нови прозор)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (отвара нови прозор)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Извор‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Индекс‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (отвара нови прозор)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (отвара нови прозор)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Извор‎: Onco Targets Ther 2013;7:13-21.

Индекс‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (отвара нови прозор)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (отвара нови прозор)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Извор‎: J Clin Oncol 2007;25(30):4722-9.

Индекс‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (отвара нови прозор)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (отвара нови прозор)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Извор‎: Blood 2020;135(24):2137-45.

Индекс‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (отвара нови прозор)